← Back to Search

Viral Load Test

Point-of-Care Tests for HIV Diagnosis (EHPOC Trial)

N/A

Recruiting

Led By Matthew Hamill, MBChB, Ph.D

Research Sponsored by Johns Hopkins University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Aged 18 years or older

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 weeks

Awards & highlights

EHPOC Trial Summary

This trial will compare the accuracy of four different kinds of point-of-care tests for HIV diagnosis, to see which is best.

Who is the study for?

This trial is for adults over 18 who are living with or at high risk for HIV, including MSM/transgender individuals, those using injection drugs, have known STIs or are being screened for them. Participants must be willing to share lab results, undergo blood and oral fluid tests, complete a questionnaire, attend follow-up visits, and allow their samples to be sent to the CDC.Check my eligibility

What is being tested?

The study is testing rapid point-of-care (POC) technologies like Cepheid GeneXpert HIV-1 Qual POC HIV VL test and others against standard lab procedures. It aims to see if these can speed up diagnosis of HIV/Syphilis and improve linking patients quickly to treatments or prevention services during one clinic visit.See study design

What are the potential side effects?

Since this trial focuses on diagnostic tests rather than medications or therapies, side effects may include discomfort from blood draws or oral fluid collection. There might also be emotional impacts due to immediate knowledge of an HIV/Syphilis diagnosis.

EHPOC Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

EHPOC Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of participants linked either to PrEP or ART

Secondary outcome measures

Change in proportion of participants reporting condom-less sex

HIV: time to linkage to either PrEP or ART

Syphilis: time to linkage to syphilis treatment

EHPOC Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: POC HIV VL TestingExperimental Treatment3 Interventions

Participants will receive the standard of care tests (DPP HIV-Syphilis Test System, OraQuick) plus the HIV POC VL test.

Group II: SOC HIV TestingActive Control2 Interventions

Participants will receive routine standard of care HIV testing.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

OraQuick

2018

N/A

~10000

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor

2,263 Previous Clinical Trials

14,822,757 Total Patients Enrolled

Centers for Disease Control and PreventionFED

875 Previous Clinical Trials

22,476,994 Total Patients Enrolled

Matthew Hamill, MBChB, Ph.DPrincipal InvestigatorJohns Hopkins University

Media Library

Cepheid GeneXpert HIV-1 Qual POC HIV VL test (Viral Load Test) Clinical Trial Eligibility Overview. Trial Name: NCT04793750 — N/A

Human Immunodeficiency Virus Infection Research Study Groups: POC HIV VL Testing, SOC HIV Testing

Human Immunodeficiency Virus Infection Clinical Trial 2023: Cepheid GeneXpert HIV-1 Qual POC HIV VL test Highlights & Side Effects. Trial Name: NCT04793750 — N/A

Cepheid GeneXpert HIV-1 Qual POC HIV VL test (Viral Load Test) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04793750 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is recruitment ongoing for this experiment?

"This medical trial is open to candidates; its listing on clinicaltrials.gov was first published in August of 2021, with the most recent update occurring a year later in 2022."

Answered by AI

How many individuals are currently involved in the experiment?

"Affirmative. According to data posted on clinicaltrials.gov, this medical trial has commenced recruitment efforts; the study was originally advertised on August 18th 2021 and its details were recently updated on August 9th 2022. The experiment requires 408 participants from 3 different healthcare facilities."

Answered by AI